Search for Clinical Trial Results

Sponsored By

Carcinoma, Merkel Cell - 25 Studies Found

Status Study
Recruiting Study Name: Avelumab in Subjects With Merkel Cell Carcinoma (JAVELIN Merkel 200)
Condition: Carcinoma, Merkel Cell
Date: 2014-06-02
Interventions: Drug: Avelumab Avelumab will be administered at a dose of 10 milligram per kilogram (mg/kg) as 1-hour in
Recruiting Study Name: MLN0128 in Recurrent/Metastatic Merkel Cell Carcinoma
Condition: Merkel Cell Carcinoma
Date: 2015-07-28
Interventions: Drug: MLN0128 Investigational mTOR kinase inhibitor
Recruiting Study Name: F16IL2 Plus Paclitaxel in Metastatic Merkel Cell Carcinoma
Condition: Merkel Cell Carcinoma
Date: 2014-01-31
Interventions:
  • Drug: Arm A: F16IL2 in combination with paclitaxel

Active, not recruiting Study Name: A Proof-of-Concept Trial of GLA-SE in Patients With Merkel Cell Carcinoma
Condition: Merkel Cell Carcinoma
Date: 2014-01-10
Interventions: Biological: GLA-SE Glucopyranosyl Lipid A in Stable Emulsion
Recruiting Study Name: Adjuvant Therapy of Completely Resected Merkel Cell Carcinoma With 3 mg/kg BW Ipilimumab (Yervoy®) Versus Observation
Condition: Merkel Cell Carcinoma
Date: 2014-06-20
Interventions: Drug: Ipilimumab adjuvant treatment of completely resected Merkel cell carcinoma
Recruiting Study Name: Treatment of Unresecable and/or Metastatic Merkel Cell Carcinoma by Somatostatine Analogues
Condition: Carcinoma, Merkel Cell
Date: 2015-01-13
Interventions: Drug: Lanreotide Other Name: Somatuline
Available Study Name: Expanded Access to Avelumab for Treatment of Metastatic Merkel Cell Carcinoma (mMCC)
Condition: Metastatic Merkel Cell Carcinoma
Date: 2017-03-20
Interventions: Drug: Avelumab Avelumab should be administered intravenously as per the recommended dose. Administration
Withdrawn Study Name: Study of the Drug Ipilimumab for Metastatic Merkel Cell Carcinoma
Condition: Merkel Cell Carcinoma
Date: 2013-07-28
Interventions: Drug: Ipilimumab Ipilimumab is a recombinant, human monoclonal antibody that binds to CTLA-4. It is comm
Completed Study Name: IL-12 Gene and in Vivo Electroporation-Mediated Plasmid DNA Vaccine Therapy in Patients With Merkel Cell Cancer
Condition: Merkel Cell Carcinoma
Date: 2011-09-23
Interventions:
  • Biological: interleukin-12 gene

Terminated Study Name: Viral Oncoprotein Targeted Autologous T Cell Therapy for Merkel Cell Carcinoma
Condition:
  • Recurrent Merkel Cell Carcinoma
  • Stage IV
    Date: 2012-12-27
    Interventions:
    • Biological: Aldesleukin Given

Next >>>